The 2026 Healthtech Messaging Index
Cleerly
cleerlyhealth.com·scored November 1, 2026
14/38
Weak
The signal is faint. Most of this page is about Cleerly, not the buyer, and AI has little it can repeat. There's a lot of room to move.
The AI Recommendation Check
When we asked AI who to recommend for AI-powered coronary artery disease (CAD) analysis and cardiac CT imaging software, it named:
Buyer we put in the prompt: Cardiologist, radiologist, or healthcare provider at a hospital or cardiology practice evaluating AI-assisted cardiac imaging software. Both the buyer and the category were inferred from Cleerly’s homepage alone. The model had no web access.
Cleerly was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI named you when asked who it recommends for "AI-powered coronary artery disease (CAD) analysis and cardiac CT imaging software", and described you accurately: "Cleerly uses AI to analyze coronary CT angiography (CCTA) images, quantifying and characterizing coronary artery plaque to help clinicians assess CAD risk and guide treatment decisions non-invasively.". Your positioning is landing with the machines.
Overall assessment
Cleerly's biggest strength is its clinical validation data ... named trials (CREDENCE, PACIFIC), specific comparators (FFRCT, SPECT), and a differentiating claim that Cleerly ISCHEMIA is the only non-invasive test prognostic of future MACE events. The biggest gap is a complete absence of customer voice: no testimonials, no named case studies, no social proof, and no cost-of-inaction framing ... the page reads like a product spec sheet aimed at early adopters who already know they want this, not a persuasive story that converts skeptical buyers.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
02Rebellion / Movement
“No named enemy, no named status quo critique, no 'the old way was X' framing anywhere on the page.”
The page never pushes against stress testing limitations, missed diagnoses, or any named industry pattern ... it is purely capability-forward with no rebellion or point of view.
All 19 signals, scored 0 to 2.
Total 14/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“Get AI-powered insights on: Stenosis Plaque volume Plaque Phenotype Ischemia likelihood Serial CCTA scans”
A clinician could piece together that this is cardiac imaging AI, but 'a caveman' cannot instantly grasp who it's for or the core problem in 7 seconds ... the hero leads with a feature list, not a clear problem-solution statement.
- 0
02Rebellion / Movementweakest
“No named enemy, no named status quo critique, no 'the old way was X' framing anywhere on the page.”
The page never pushes against stress testing limitations, missed diagnoses, or any named industry pattern ... it is purely capability-forward with no rebellion or point of view.
- 1
03Owned Language & Category
“Cleerly ISCHEMIA" and "Plaque Phenotype" appear as product-specific terms.”
Cleerly has branded product names like 'Cleerly ISCHEMIA' and uses 'Plaque Phenotype,' but no overarching category or named framework is claimed or defined that AI could quote as Cleerly's own invention.
- 1
04ICP Clarity
“FOR PAYORS & PROVIDERS" / "FOR HEALTHCARE PROVIDERS" / "FOR PATIENTS”
Three audience buckets are named but none specify role, practice size, specialty, or clinical context precisely enough for a visitor to immediately self-identify as the right buyer.
- 0
05Problem Leadership
“No problem-first framing anywhere above the fold; the page opens with a product feature list.”
The page leads entirely with solution capabilities and AI features, never articulating the buyer's problem ... missed diagnoses, diagnostic uncertainty, or patient risk ... in the buyer's own language.
- 1
06Solution Clarity
“Cleerly is a comprehensive, AI-driven platform that quantifies and assesses coronary artery disease (CAD) to deliver clinically actionable insights”
A visitor can roughly explain what Cleerly does, but 'comprehensive AI-driven platform' and 'clinically actionable insights' are generic enough that the one-sentence takeaway is blurry, not crisp.
- 0
07Cost of Inaction
“No cost-of-inaction language anywhere on the page ... no mention of missed diagnoses, delayed treatment, or patient harm from not changing.”
The page never names what happens if a provider keeps using their current approach ... the stakes of inaction are completely absent.
- 1
08Promised Land
“potentially reducing the need for additional testing and enhancing diagnostic confidence”
There is a vague 'after state' implied (fewer tests, more confidence) but it is hedged with 'potentially' and never painted as a vivid, specific promised land for the buyer's practice or patients.
Trust Signal
4 signals
- 1
09Proof & Evidence
“higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing, as referenced to 868 invasive measurements”
Clinical trial data with specific reference numbers exists, but there are no before/after operational deltas, no outcome numbers tied to real-world practice impact, and no patient volume or revenue proof points.
- 0
10Social Proof
“No customer logos, no named testimonials with titles, no case studies, no video stories from named customers anywhere on the page.”
The page shows award badges but zero social proof from actual customers ... no quotes, no names, no companies, no case studies.
- 1
11Authority & Credibility
“Award badges shown: "Digital Health Best in Class," "AI Breakthrough Award Best Overall," "Fierce 15 Award," "Rock Health Top 50 in Digital Health”
Awards are present and lend some credibility, but founder credentials, original research authorship, frameworks, or books are absent ... authority is claimed via badges, not demonstrated through expertise.
- 0
12Alternatives Acknowledged
“No mention of alternative approaches, competitors, or the 'do nothing' option anywhere on the page.”
The page never acknowledges that buyers have other options (stress testing, FFRCT, or doing nothing), missing the trust signal of honest competitive context.
AI Signal
6 signals
- 1
13Customer Focus
“Collaborating with Cleerly for cardiac care assessments may empower better treatment decisions and improve diagnostic testing and patient outcomes”
The page oscillates between company capabilities and customer outcomes but tilts toward describing Cleerly's technology rather than the customer's transformation story.
- 1
14AI-Parmesan Index
“Get AI-powered insights on: Stenosis Plaque volume Plaque Phenotype Ischemia likelihood”
AI is referenced with some specificity (machine learning variables, specific measurement outputs) but 'AI-powered insights' in the hero is generic sprinkle; the mechanistic detail is buried below the fold.
- 1
15LLM Quotability
“Cleerly ISCHEMIA was the only non-invasive ischemia test that was prognostic of future MACE events, FFRCT and SPECT were not”
This sentence is close to LLM-quotable with a specific comparative claim, but most of the page's language is hedged ('may,' 'potentially') or too jargon-dense for clean AI citation.
- 0
16Copyright Freshness
“No visible dates on blog posts, case studies, or content; no copyright year visible in the scraped content.”
There are zero recency signals in the scraped content ... no dated publications, no recent case studies, no current copyright year ... giving AI engines nothing to weight for freshness.
- 1
17Entity Distinctiveness
“Cleerly ISCHEMIA demonstrated higher diagnostic accuracy... compared to FFRCT and stress testing, as referenced to 868 invasive measurements”
The specific product names and clinical trial references (CREDENCE, PACIFIC) give some distinctiveness, but the core positioning ('AI-driven platform for CAD') is interchangeable with several cardiac AI competitors.
- 2
18AI Recommendation Check
“AI described you as: "Cleerly uses AI to analyze coronary CT angiography (CCTA) images, quantifying and characterizing coronary artery plaque to help clinicians assess CAD risk and guide treatment decisions non-invasively.”
AI named you when asked who it recommends for "AI-powered coronary artery disease (CAD) analysis and cardiac CT imaging software", and described you accurately: "Cleerly uses AI to analyze coronary CT angiography (CCTA) images, quantifying and characterizing coronary artery plaque to help clinicians assess CAD risk and guide treatment decisions non-invasively.". Your positioning is landing with the machines.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“Request a Demo" CTA appears multiple times; no visible numbered process or soft secondary CTA differentiated from the primary.”
There is a clear primary CTA ('Request a Demo') repeated, but no numbered path explaining what happens next and no distinct soft secondary option ... only a repeated hard CTA.
Keep the lead
AI already names Cleerly. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Cleerly the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.